Allan S. Brett
Abstract
Metformin and the thiazolidinediones (e.g., pioglitazone [Actos] and rosiglitazone [Avandia]) are increasingly popular first-line drugs for type 2 diabetes. In this randomized, double-blind multicenter study from Europe, 1199 patients with type 2 diabetes and inadequate responses to diet alone received either metformin (titrated …
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Metformin and the thiazolidinediones (e.g., pioglitazone [Actos] and rosiglitazone [Avandia]) are increasingly popular first-line drugs for type 2 diabetes. In this randomized, double-blind multicenter study from Europe, 1199 patients with type 2 diabetes and inadequate responses to diet alone received either metformin (titrated …
Key concepts: Pioglitazone, Metformin, Medicine, Rosiglitazone, Type 2 diabetes, Diabetes mellitus, Internal medicine, First line